Home
 /
Papers
 /
Molecular Biology
 /
Antiviral reverse transcriptases reveal the evolutionary origin of telomerase
Preprint
Open access
V1
Top 1% · Validated by QED

Antiviral reverse transcriptases reveal the evolutionary origin of telomerase

Stephen Tang, Josephine L. Ramirez, Mario Rodríguez Mestre +7 more
October 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.10.16.682844
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Molecular Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By identifying a bacterial antiviral reverse transcriptase that synthesizes tandem-repeat DNA via a telomerase-like mechanism, this work traces telomerase's origin to prokaryotic immunity, overturning retroelement origin models and rewriting the evolutionary history of chromosome maintenance.

QED claims analysis

Summary

A bacterial antiviral defense system, DRT10, employs a telomerase-like mechanism of RNA-templated tandem-repeat DNA synthesis through protein-primed reverse transcription directed by an A-B-A′ sequence pattern in its associated ncRNA, and phylogenetic analysis reveals that eukaryotic telomerase reverse transcriptase (TERT) is evolutionarily related to bacterial Class 2 UG reverse transcriptases, indicating that telomerase originated in bacteria before being co-opted for chromosome maintenance in eukaryotes.

See full analysis
Main Claim 1 –

DRT10 is a tripartite RT–SLATT–ncRNA phage defense system

Supporting evidence

  • DRT10 ncRNA has conserved central and accessory stem-loop structures
Main Claim 2 –

DRT10 constitutively makes ncRNA-templated single-stranded tandem-repeat cDNA

Supporting evidence

  • Purified DRT10 RT and ncRNA reconstitute single-stranded cDNA synthesis in vitro
  • DRT10 is serine-primed via a conserved C-terminal residue
Main Claim 3 –

ncRNA A–B–A′ pattern drives processive DRT10 repeat synthesis

Supporting evidence

  • A–B–A′ templating mechanism is conserved across diverse DRT10 ncRNAs
Main Claim 4 –

TERT is phylogenetically linked to bacterial Class 2 UG RTs

Supporting evidence

  • Structural similarity supports a close TERT–Class 2 UG RT relationship

Abstract

Defense-associated reverse transcriptases (DRTs) employ diverse and distinctive mechanisms of cDNA synthesis to protect bacteria against viral infection. However, much of DRT family diversity remains unstudied. Here we identify a new antiviral defense system, DRT10, that associates with a non-coding RNA (ncRNA) to catalyze processive, protein-primed synthesis of tandem-repeat DNA. Repeat addition is dictated by sequence and structural features of the ncRNA that have direct parallels in the RNA component of telomerase. Remarkably, a phylogenetic analysis of RTs across domains of life reveals an unexpected link between DRT10 and telomerase that is further supported by structural comparisons and mechanistic evidence. These findings expand the repertoire of reverse transcription mechanisms in antiviral defense and point to a bacterial origin for telomerase.

Insights from antiviral defense systems reveal an unexpected bacterial origin for the mechanism of chromosome maintenance by eukaryotic telomerase.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?